Trastuzumab deruxtecan - Wikipedia
WEBTrastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan (a derivative of exatecan).
Mechanism of Action | ENHERTU® (fam-trastuzumab deruxtecan …
WEBThe latest research and development into the antibody–drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull (Tokyo). 2019;67(3):173-175.
Trastuzumab Deruxtecan (Enhertu) - NCBI Bookshelf
WEBpERC acknowledged trastuzumab deruxtecan fulfills the need for a targeted therapy in patients with unresectable or metastatic HER2-low breast cancer who have received 1 or more prior lines of chemotherapy.
Trastuzumab - StatPearls - NCBI Bookshelf
WEBJun 22, 2024 · Trastuzumab deruxtecan is a trastuzumab conjugate that releases its cytotoxic components after binding and entering HER2-expressing cells, effectively treating HER2-positive gastric, lung, colorectal, and metastatic breast cancer.
Trastuzumab Deruxtecan in Previously Treated HER2-Low …
WEBJun 5, 2022 · Trastuzumab deruxtecan (formerly DS-8201), an antibody–drug conjugate consisting of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload through a...
Trastuzumab Deruxtecan: Changing the Destiny of HER2 …
WEBApr 30, 2021 · Trastuzumab deruxtecan (T-DXd) is a novel HER2-directed antibody drug conjugate showing significant anti-tumor activity in heavily pre-treated HER2-positive breast and gastric cancer patients. Preliminary data have shown promising objective response rates in patients with HER2-positive NSCLC and colorectal cancer.
Trastuzumab Deruxtecan: Changing the Destiny of HER2 …
WEBApr 30, 2021 · Trastuzumab deruxtecan (T-DXd) is a novel HER2-directed antibody drug conjugate showing significant anti-tumor activity in heavily pre-treated HER2-positive breast and gastric cancer patients. Preliminary data have shown promising objective response rates in patients with HER2-positive NSCLC and colorectal cancer.
WEBTrastuzumab deruxtecan is an antibody-drug conjugate (ADC) that contains a humanised anti- HER2 IgG1 monoclonal antibody (mAb) with the same amino acid sequence as trastuzumab, produced by mammalian (Chinese Hamster Ovary) cells, covalently linked to DXd, an exatecan
Trastuzumab deruxtecan in metastatic breast cancer with ... - Nature
WEBJul 24, 2023 · Trastuzumab deruxtecan, an anti-HER2–drug conjugate, exhibits the highest objective response rate in patients with HER2-overexpressing metastatic breast cancer, but clinical activity is also ...
Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell …
WEBSep 18, 2021 · Trastuzumab deruxtecan (formerly DS-8201) is an antibody–drug conjugate consisting of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload through a...
Skip to content